Cure My Disease

Don't miss your cure!

 Log in / Sign up

A simple scan and blood test could catch silent liver scarring before It's too late

NCT ID NCT07775638

Diagnosis Sponsor: Helse Stavanger HF Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This study is testing whether a combination of simple, non-invasive tests—like a liver scan and blood samples—can accurately detect advanced liver fibrosis (scarring) in people at risk for fatty liver disease. Researchers will follow 1,200 adults aged 40 to 70 who have obesity, type 2 diabetes, or risky alcohol consumption, tracking them for many years with regular check-ups. The goal is to find a reliable way to identify serious liver damage early, potentially preventing progression to cirrhosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Routine study procedures including liver elastography, blood sampling, and questionnaires
What this could lead to
If successful, this could lead to simple, non-invasive ways to detect advanced liver scarring early, potentially preventing progression to cirrhosis.
What could go wrong
The study is observational and long-term, so results will take years. The accuracy of the tests may vary, and they might not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2070

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adults recruited from the primary healthcare setting in Southern part of Rogaland County, Norway. Participants are identified through general practitioners and other primary care services and include community-dwelling individuals aged 40-70 years with metabolic and/or lifestyle-related risk factors for steatotic liver disease. All study visits and assessments are conducted at Stavanger University Hospital.

Ages

40 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 40 to 70 years at the time of inclusion * At least one of the following risk factors: Overweight or obesity, type 2 diabetes mellitus, risky or harmful alcohol consumption * Ability to provide written informed consent Exclusion Criteria: * Inability to give informed consent * Individuals outside the defined age range * Other conditions precluding participation based on investigator assessment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biomarker in early diagnosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver fatty liver disease Fibrosis liver disorder metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biomarker in early diagnosis Cirrhoses, liver Fatty liver Liver disease (alcoholic or not) Masld (metabolic dysfunction-associated steatotic liver disease) NAFLD - non-alcoholic fatty liver disease NASH

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Stavanger University Hospital

    Stavanger, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.